NIH-funded research R21 grant

Improving newborn screening for cystic fibrosis to be more accurate and fair

Official title: Optimal newborn screening algorithms - efficacy and equity

Funded at University of Alabama in Tuscaloosa · NIH-11190804 · Data updated 2026-11-12

Develops and compares newborn screening methods to improve detection of cystic fibrosis in newborns, with attention to fairness for African American babies.

More Newborn research and trials

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionUniversity of Alabama in Tuscaloosa
NIH-funded
Lab location1 site (Tuscaloosa, United States)
Project startSeptember 10, 2024
Project endAugust 31, 2026
Funding year2025
Award (this year)$186,250
NIH project number5R21HD113958-02
Project IDNIH-11190804 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates are newborns in the first days or weeks of life whose parents are willing to provide or allow use of their routine newborn screening bloodspot data and follow-up information.

Less likely to help

Older children, adults, or families not involved in newborn screening programs are unlikely to benefit directly from this project.

What this research studies

If your baby is part of this work, researchers will examine how current newborn screening steps (a low-cost blood test, follow-up genetic testing, and confirmatory sweat testing) are combined across different places. They will use existing dried blood spot results and screening data to model alternative decision rules, such as different test thresholds and which genetic variants to include. The team aims to balance detecting true cases, avoiding unnecessary follow-ups, and keeping costs reasonable, while explicitly checking performance for African American infants. Results will be used to propose screening algorithms that states could adopt to reduce missed diagnoses and false alarms.

Why it matters

Potential benefit: Could lead to earlier and more reliable cystic fibrosis detection for newborns, reduce unnecessary follow-up tests, and reduce racial disparities in screening outcomes.

How similar studies have gone: Past work changing screening thresholds and mutation panels has improved detection in some settings, but this project is broader and explicitly targets fairness across groups, so it is partly novel.

Where this research is happening

  • University of Alabama in Tuscaloosa
    Tuscaloosa, United States
    Active

Researchers

  • Principal investigator: Bish, Douglas — University of Alabama in Tuscaloosa
  • Study coordinator: Bish, Douglas

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.